Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech
Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if…
March 16, 2018 - 2 minutes
Prexton Therapeutics
Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s
Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat…
July 10, 2017 - 2 minutes
In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…
May 30, 2017 - 7 minutes
Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs
Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials…
February 7, 2017 - 2 minutes
ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug
For our first interview at the SACHS Conference in Basel yesterday, I met with François Conquet, founder…
September 28, 2016 - 1 minute
Infographic: The Anatomy of European Biotech
Which part of our body do European biotechs prefer to target? And how diversified are…
December 10, 2015 - 1 minute
